INDUSTRY SESSIONS
Details on the industry sessions can be found below. Register for these sessions via the online registration form.
Industry Breakfast Sponsor
| Date | Tuesday, 6 May 2024 |
|---|---|
| Time | 07:00 - 08:00 |
| Location | Central Room C, Ground Floor, Gold Coast Convention and Exhibition Centre |
| Session Title | Pharmacogenetics in Psychiatry |
| Speakers | | |
| Session Synopsis | Pharmacogenomics is increasingly used by psychiatrists to proactively guide the prescribing of new medications, or reactively if treatment fails. This session explores the medications for which there is prescribing guidance available based on the results of pharmacogenomic testing, and how these results may be used to personalise treatment plans. |
| Breakfast | 🍽️ Breakfast will be provided |
Professor Luke Hesson
Professor Luke Hesson is a Clinical Scientist with more than 20 years’ experience in cancer research and genetic pathology. He holds a doctorate in Clinical Genetics and is a Fellow of the Faculty of Science of the Royal College of Pathologists of Australasia (RCPA). As Manager of the Genetics Department at Douglass Hanly Moir Pathology, Luke provides scientific supervision of genetic testing including pharmacogenomics and comprehensive genomic profiling for cancer. He is affiliated with UNSW Sydney and University of Technology Sydney where he lectures in genetics, epigenetics, cancer, pathology and precision medicine. Luke is Vice-Chair of the Australasian Society for Diagnostic Genomics (ASDG) and co-Chair of the RCPA Pharmacogenetic Advisory Group, which recently provided guidance for prescribers, pharmacologists and pathologists regarding clinical indications for pharmacogenomics testing in Australia.
Dr Tom Polasek
Dr. Tom Polasek is a Clinical Pharmacologist who works in the healthcare, life sciences and tertiary education sectors. Tom’s main interest is the application of clinical pharmacology principles to improve patient care. He is the author of 150 peer-reviewed articles and conference presentations. Tom has been an Investigator on over 150 clinical studies and has supported countless drug development programs. Tom is Associate Medical Director of CMAX Clinical Research in Adelaide and is an Adjunct Senior Research Fellow at Monash University in Melbourne. Tom is also a Fellow of the American College of Clinical Pharmacology.
Thank you to our destination supporter
Privacy ©2025
RANZCP 2025 Congress